Investigator-Initiated Phase 2 study is being conducted at Northwestern University in cooperation with Moleculin. Trial combines WP1066 and radiation, which demonstrated both significant therapeutic response and immune "memory" in glioblastoma animal models
Under terms of the agreement, AbbVie and Gilgamesh Pharmaceuticals have agreed to research and develop a portfolio of next-generation therapeutics for psychiatric disorders.
Investigator-Initiated Phase 2 study is being conducted at Northwestern University in cooperation with Moleculin. Trial combines WP1066 and radiation, which demonstrated both significant therapeutic response and immune "memory" in glioblastoma animal models
William ‘Obi’ Greenman, Cerus’ president and chief executive officer explains, “This is a significant milestone for Cerus and highlights the scope our technology has had within the transfusion industry and on the millions of patients worldwide transfused with INTERCEPT treated platelet and plasma components. “We have a solid track record with the safety and efficacy of our INTERCEPT products, which now surpasses more than 7.5 million treatable doses.”
Under the terms of the agreements, PATHNOVA will be responsible for the further development and commercialization of the Todos Tests in Singapore, and Todos Medical will assist PATHNOVA in commercializing its nasopharyngeal cancer tests through its affiliates in the United States and Singapore.
Veracyte and MAVIDx agreement is intended to enable diagnostic testing and population screening for COVID-19 at an unprecedented scale – up to 40,000 samples per day performed on the easy-to-use nCounter instrument – through technology that attaches molecular barcodes to individual RNA molecules of the virus.
Ensuring an added level of safety, the new filters can be used with ndd’s revolutionary, and highly portable EasyOne® spirometry range, including the EasyOne Air, EasyOne Pro, and EasyOne Pro LAB.
The new voice-enabled health detection and monitoring app from Sonde Health promises to potentially help employers improve employee safety, meet government mandates, and satisfy their own administrative needs as they reopen office doors in a rapidly changing COVID-19 environment.
This contract contains a minimum of 76,000 paid cancer screening tests, including at least 6,000 paid tests in 2020, 25,000 paid tests in 2021, and 45,000 paid tests in 2022.
This will provide a significant increase in its manufacturing footprint, resulting in Europe’s largest capacity for rapid test manufacturing. This news comes weeks after the UK Government announced Abingdon Health as one of the leading members of the UK Rapid Test Consortium
By using this website you agree to accept Medical Device News Magazine Privacy Policy
